Literature DB >> 8727077

Partial inhibition of vesicular stomatitis virus by the interferon-induced human 9-27 protein.

D Alber1, P Staeheli.   

Abstract

To determine whether the interferon-induced 9-27 protein of human cells contributes to the antiviral state, we expressed the 9-27 cDNA under the control of a constitutive promoter and assayed transfected cells for enhanced virus resistance. The intracellular distribution of 9-27 resembled that of cytoskeleton-associated proteins. Analysis at the single-cell level by indirect immunofluorescence revealed that mouse cells expressing 9-27 were less permissive for vesicular stomatitis virus than control cells not expressing 9-27. No significant inhibition of influenza virus was observed. When tested in parallel, 9-27 was found to have less powerful antiviral activity toward vesicular stomatitis virus than the interferon-induced MxA protein. Thus, 9-27 joins the family of interferon-induced proteins with intrinsic antiviral activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8727077     DOI: 10.1089/jir.1996.16.375

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  19 in total

1.  Resveratrol trimer enhances gene delivery to hematopoietic stem cells by reducing antiviral restriction at endosomes.

Authors:  Stosh Ozog; Nina D Timberlake; Kip Hermann; Olivia Garijo; Kevin G Haworth; Guoli Shi; Christopher M Glinkerman; Lauren E Schefter; Saritha D'Souza; Elizabeth Simpson; Gabriella Sghia-Hughes; Raymond R Carillo; Dale L Boger; Hans-Peter Kiem; Igor Slukvin; Byoung Y Ryu; Brian P Sorrentino; Jennifer E Adair; Scott A Snyder; Alex A Compton; Bruce E Torbett
Journal:  Blood       Date:  2019-10-17       Impact factor: 22.113

2.  IFITM-Family Proteins: The Cell's First Line of Antiviral Defense.

Authors:  Charles C Bailey; Guocai Zhong; I-Chueh Huang; Michael Farzan
Journal:  Annu Rev Virol       Date:  2014-11-01       Impact factor: 10.431

Review 3.  Filovirus Strategies to Escape Antiviral Responses.

Authors:  Judith Olejnik; Adam J Hume; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler; Elke Mühlberger
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

4.  Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3.

Authors:  Jacob S Yount; Bruno Moltedo; Yu-Ying Yang; Guillaume Charron; Thomas M Moran; Carolina B López; Howard C Hang
Journal:  Nat Chem Biol       Date:  2010-07-04       Impact factor: 15.040

5.  Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein.

Authors:  M K Chelbi-Alix; F Quignon; L Pelicano; M H Koken; H de Thé
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

6.  Normal germ line establishment in mice carrying a deletion of the Ifitm/Fragilis gene family cluster.

Authors:  Ulrike C Lange; David J Adams; Caroline Lee; Sheila Barton; Robert Schneider; Allan Bradley; M Azim Surani
Journal:  Mol Cell Biol       Date:  2008-05-27       Impact factor: 4.272

7.  The Interferon-Stimulated Gene Ifitm3 Restricts West Nile Virus Infection and Pathogenesis.

Authors:  Matthew J Gorman; Subhajit Poddar; Michael Farzan; Michael S Diamond
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

8.  The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.

Authors:  Abraham L Brass; I-Chueh Huang; Yair Benita; Sinu P John; Manoj N Krishnan; Eric M Feeley; Bethany J Ryan; Jessica L Weyer; Louise van der Weyden; Erol Fikrig; David J Adams; Ramnik J Xavier; Michael Farzan; Stephen J Elledge
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

Review 9.  Membrane Interference Against HIV-1 by Intrinsic Antiviral Factors: The Case of IFITMs.

Authors:  Federico Marziali; Andrea Cimarelli
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

10.  Ifitm3 limits the severity of acute influenza in mice.

Authors:  Charles C Bailey; I-Chueh Huang; Christina Kam; Michael Farzan
Journal:  PLoS Pathog       Date:  2012-09-06       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.